完带汤联合重组人干扰素α-2b凝胶对宫颈高危型HPV感染的疗效分析  

Efficacy of Wandai decoction combined with recombinant human interferonα-2b gel in treating high-risk HPV infection of the cervix and its impacts on vaginal microecology and immune function

作　　者：周芬 何小赟 ZHOU Fen;HE Xiaoyun(Gynecology,Changxing Maternal and Child Health Hospital,Huzhou 313100,Zhejiang,China)

机构地区：[1]长兴县妇幼保健院妇科,浙江湖州313100

出　　处：《中国病原生物学杂志》2024年第3期333-336,共4页Journal of Pathogen Biology

基　　金：湖州市科学技术局公益性应用研究项目(No.2023GY58)。

摘　　要：目的探讨完带汤联合重组人干扰素α-2b(rhIFNα-2b)凝胶治疗宫颈高危型人乳头状瘤病毒(HR-HPV)感染的疗效。方法选择2022年8月-2023年8月本院收治的宫颈HR-HPV感染患者80例,依据随机数字表法分为对照组(40例,予rhIFNα-2b凝胶)、研究组(40例,予完带汤联合rhIFNα-2b凝胶)。比较中医证候疗效、中医证候积分、HR-HPV转阴率、阴道微生态正常率、免疫功能以及阴道灌洗液人β-防御素-2(HBD-2)、人防御素-5(HD-5)。结果研究组的总有效率(92.50%,37/40)、HR-HPV转阴率(70.00%,28/40)、阴道微生态正常率(77.50%,31/40)高于对照组(75.00%,30/40)、(40.00%,16/40)、(52.50%,21/40)(P<0.05)。治疗后,两组的中医证候积分[(7.35±1.14)分、(4.46±1.02)分]、HBD-2[(429.81±55.85)ng/L、(360.68±54.23)ng/L]、HD-5[(37.01±5.12)ng/L、(30.13±4.06)ng/L]均低于治疗前[(14.16±1.81)分、(13.47±1.93)分、(550.52±70.61)ng/L、(555.43±71.14)ng/L、(46.58±6.02)ng/L、(47.22±5.85)ng/L](P<0.05),且研究组低于对照组(P<0.05)。治疗后,两组的免疫球蛋白(Ig)G、IgM、IgA、CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于治疗前(P<0.05),且研究组高于对照组(P<0.05)。结论完带汤联合rhIFNα-2b凝胶治疗宫颈HR-HPV感染疗效显著,可改善中医证候、免疫功能,促进HR-HPV转阴、阴道微生态正常,并降低HBD-2、HD-5。Objective To explore the efficacy of Wandai decoction combined with recombinant human interferonα-2b(rhIFNα-2b)gel in treating high-risk human papilloma virus(HR-HPV)infection of the cervix.Methods Eighty patients with cervical HR-HPV infection accepted by our hospital from August 2022 to August 2023 were collected and randomly separated into a reference group(40 cases,treated with rhIFN)and trail group(40 cases,given Wandai decoction combined with rhIFNα-2b gel)using random number table method.The efficacy of traditional Chinese medicine(TCM)syndrome,TCM syndrome score,HR-HPV negative conversion rate,vaginal microbiota normal rate,immune function,and vaginal lavage fluid humanβ-defensin 2(HBD-2)and human defensin 5(HD-5)were compared.Results The total effective rate(92.50%,37/40),HR-HPV negative conversion rate(70.00%,28/40),and vaginal microbiota normal rate(77.50%,31/40)of the trail group were higher than those of the reference group(75.00%,30/40),(40.00%,16/40),and(52.50%,21/40)(P<0.05).After treatment,the TCM syndrome scores[(7.35±1.14)score,(4.46±1.02)score],HBD-2[(429.81±55.85)ng/L,(360.68±54.23)ng/L],and HD-55[(37.01±5.12)ng/L,(30.13±4.06)ng/L]of both groups were lower than before treatment[(14.16±1.81)score,(13.47±1.93)score,(550.52±70.61)ng/L,(555.43±71.14)ng/L,(46.58±6.02)ng/L,(47.22±5.85)ng/L](P<0.05),and the trail group were lower than the reference group(P<0.05).After treatment,the levels of immunoglobulin(Ig)G,IgM,IgA,CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in both groups were higher than before treatment(P<0.05),and the trail group were higher than the reference group(P<0.05).Conclusion Wandai decoction combined with rhIFNα-2b gel is effective in treating cervical HR-HPV infection,which can improve TCM syndrome and immune function,promote the conversion of HRHPV to negative,vaginal microecology to be normal,and reduce HBD-2 and HD-5.

关 键 词：完带汤 重组人干扰素Α-2B凝胶 宫颈 高危型 人乳头状瘤病毒 疗效 阴道微生态 免疫功能 

分 类 号：R711.32[医药卫生—妇产科学]